T-CELL LYMPHOMAS
Clinical trials for T-CELL LYMPHOMAS explained in plain language.
Never miss a new study
Get alerted when new T-CELL LYMPHOMAS trials appear
Sign up with your email to follow new studies for T-CELL LYMPHOMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to tame rare blood cancers
Disease control Recruiting nowThis early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…
Matched conditions: T-CELL LYMPHOMAS
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 22:02 UTC
-
New drug combo aims to outdo chemo for rare blood cancer
Disease control Recruiting nowThis study tests a new two-drug combination (GW5282 and golidocitinib) for people with T-cell lymphoma, a rare blood cancer. The first part finds the safest dose; the second part compares the combo's effectiveness to standard chemotherapy. About 165 adults with newly diagnosed or…
Matched conditions: T-CELL LYMPHOMAS
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC